Y-Biologics (XKRX:338840) Debt-to-Asset : 0.03 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Debt-to-Asset?

Y-Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩180 Mil. Y-Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩690 Mil. Y-Biologics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ₩26,818 Mil. Y-Biologics's debt to asset for the quarter that ended in Mar. 2024 was 0.03.

Y-Biologics Debt-to-Asset Historical Data

The historical data trend for Y-Biologics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Debt-to-Asset Chart

Y-Biologics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.06

0.15

0.11

0.16

0.17

Y-Biologics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial				0.10	0.10	0.14	0.10	0.03

Competitive Comparison of Y-Biologics's Debt-to-Asset

For the Biotechnology subindustry, Y-Biologics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Y-Biologics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-Biologics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Y-Biologics's Debt-to-Asset falls into.

Y-Biologics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Y-Biologics's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4751.575	+	188.099)	/	29322.649
	=	0.17

Y-Biologics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(180.1	+	689.604)	/	26817.592
	=	0.03

Y-Biologics (XKRX:338840) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Y-Biologics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Y-Biologics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-Biologics (XKRX:338840) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR

Website

https://www.ybiologics.com

Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines